Fund update: DNB Health Care & DNB Biotechnology

Join us for an update on DNB Asset Management's Healthcare and Biotechnology Funds, where our Portfolio Managers shares key insights and strategies in navigating the current market landscape.

Sottotitoli: sottotitolato nella lingua originale e tradotto nelle altre lingue con l'ausilio dell'IA. Non ci assumiamo alcuna responsabilità per eventuali errori linguistici nella traduzione. Selezionare una lingua oppure attivare/disattivare i sottotitoli avviando il video e facendo clic sul fumetto in basso a destra.

Subtitles: Texted in English and translated using AI into Spanish, German and French. We disclaim any potential language errors in the translation. Select your preferred language or turn subtitles on/off by starting the video and clicking the speech bubble in the bottom right corner.

------

In this webinar, Portfolio Manager Rune Sand-Holm, from DNB Asset Management provide an in-depth analysis of the performance and strategic adjustments of the DNB Fund Healthcare and DNB Fund Biotechnology.

Despite recent market challenges, our team highlights the long-term growth potential driven by demographic shifts, lifestyle diseases, and innovation.

Learn about our focused investments in leading companies within obesity treatment, neurology, gene editing technologies, and autoimmune diseases, and discover how we are positioning our portfolios to capitalize on these opportunities.

-------

This is marketing communication. Historical returns are no guarantee of future returns. For more information and all legal documentation, please refer to https://www.dnbam.com

(function() { var tag = document.createElement('script'); tag.src = "https://plausible.io/js/script.outbound-links.pageview-props.tagged-events.js"; tag.defer = true; tag.setAttribute("data-domain", "dnbam.com"); var firstScriptTag = document.getElementsByTagName('script')[0]; firstScriptTag.parentNode.insertBefore(tag, firstScriptTag); })();